Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications

Abstract

To the Editor: The treatment options for hairy-cell leukemia (HCL) have increased rapidly in the last 10 to 15 years. HCL patients currently can benefit from several agents such as α-interferon (α-IFN), deoxycoformycin (DCF), and 2-chlorodeoxyadenosine (2-CdA). Despite complete remission (CR)